Remove 2025 Remove Biomarkers Remove Innovation
article thumbnail

5 Most-Cited Takeaways From the 19th Annual Cardiometabolic Health Congress (CMHC) 

Cardiometabolic Health Congress

Attendees, including hundreds of health professionals, gained access to the latest knowledge and developments in the field, from exclusive insights from one of the foremost authorities on atherosclerosis, Dr. Peter Libby, to innovations like new therapeutic agents and exciting advancements in renal protection.

CME 103
article thumbnail

Primary Prevention Takes Center Stage at the 19th Annual Cardiometabolic Health Congress (CMHC)

Cardiometabolic Health Congress

The Hilton Boston Park Plaza became a hub of innovation, education, and collaboration, uniting nearly 500 clinicians under a shared mission: to redefine cardiometabolic care. The 19th Annual CMHC was more than just CME/CE medical education—it ignited global collaboration and inspired groundbreaking innovations. Learn more now!

CME 64
article thumbnail

The legal case – naming a few names

Dr. Malcolm Kendrick

(2022-25) Swiss Reinsurance Company: £645K China Kadoorie Biobank (2002-ongoing) AstraZeneca: $300K Bayer AG: £300K GlaxoSmithKline: £3.6M Elinogrel feasibility trial (2010-2011) Novartis: £500K EMPA-KIDNEY (2017-ongoing) Boehringer Ingelheim: £106.3M Establishing Fuwai-Oxford research centre (2010-ongoing) Merck: £1.1M